{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+intravenous",
    "query": {
      "intervention": "Placebo, intravenous"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2346,
    "total_pages": 235,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C+intravenous&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T21:01:22.261Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03406780",
      "title": "A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscular Dystrophies",
        "Muscular Dystrophy, Duchenne",
        "Muscular Disorders, Atrophic",
        "Muscular Diseases",
        "Neuromuscular Diseases",
        "Nervous System Diseases",
        "Genetic Diseases, X-Linked",
        "Genetic Diseases, Inborn"
      ],
      "interventions": [
        {
          "name": "CAP-1002",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Capricor Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "10 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2018-04-04",
      "completion_date": "2020-03-10",
      "has_results": true,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-09-29T21:01:22.261Z",
      "location_count": 9,
      "location_summary": "Sacramento, California • Aurora, Colorado • Orlando, Florida + 6 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03406780"
    },
    {
      "nct_id": "NCT01901588",
      "title": "Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Strabismus",
        "Delirium on Emergence",
        "Pediatric Disorders"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "7 Years",
        "sex": "ALL",
        "summary": "1 Year to 7 Years"
      },
      "enrollment_count": 63,
      "start_date": "2012-03",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2016-07-11",
      "last_synced_at": "2026-09-29T21:01:22.261Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01901588"
    },
    {
      "nct_id": "NCT02789241",
      "title": "Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Endotoxin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Robert J Noveck, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 23,
      "start_date": "2016-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-04-11",
      "last_synced_at": "2026-09-29T21:01:22.261Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02789241"
    },
    {
      "nct_id": "NCT02497469",
      "title": "An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Vedolizumab",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab placebo",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Vedolizumab placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 771,
      "start_date": "2015-06-29",
      "completion_date": "2019-01-18",
      "has_results": true,
      "last_update_posted_date": "2020-01-28",
      "last_synced_at": "2026-09-29T21:01:22.261Z",
      "location_count": 77,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 70 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02497469"
    },
    {
      "nct_id": "NCT07552766",
      "title": "A Clinical Trial on the Use of Lidocaine Infusion During Surgery for Pediatric Upper Extremity Fractures and Its Impact on Total Perioperative Opioid Requirements",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fracture Arm",
        "Fracture Closed of Lower End of Forearm, Unspecified",
        "Fracture Elbow",
        "Fracture Fixation",
        "Fracture Fixation, Internal",
        "Fracture Forearm",
        "Fracture Distal Radius"
      ],
      "interventions": [
        {
          "name": "Lidocaine Infusion",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Nemours Children's Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 90,
      "start_date": "2026-06-24",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-09-29T21:01:22.261Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07552766"
    },
    {
      "nct_id": "NCT01007942",
      "title": "Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HER2/Neu Over-expressing Locally Advanced Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 569,
      "start_date": "2009-10",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2017-04-05",
      "last_synced_at": "2026-09-29T21:01:22.261Z",
      "location_count": 43,
      "location_summary": "Tucson, Arizona • La Jolla, California • Greenwood Village, Colorado + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01007942"
    },
    {
      "nct_id": "NCT01216241",
      "title": "Daptomycin Versus Placebo in Patients With Neutropenia and Fever",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Febrile Neutropenia"
      ],
      "interventions": [
        {
          "name": "Daptomycin",
          "type": "DRUG"
        },
        {
          "name": "Saline Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2011-04",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-04-10",
      "last_synced_at": "2026-09-29T21:01:22.261Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01216241"
    },
    {
      "nct_id": "NCT02291029",
      "title": "Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Sjögren's Syndrome"
      ],
      "interventions": [
        {
          "name": "CFZ533 active - Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "CFZ533 placebo- Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "CFZ533 active - Cohort 2",
          "type": "DRUG"
        },
        {
          "name": "CFZ533 placebo - Cohort 2",
          "type": "DRUG"
        },
        {
          "name": "CFZ533 active - Cohort 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 69,
      "start_date": "2014-10-22",
      "completion_date": "2018-06-29",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-09-29T21:01:22.261Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02291029"
    },
    {
      "nct_id": "NCT01693653",
      "title": "Tocilizumab for the Treatment of Behcet's Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Behcet Syndrome"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2012-09",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-09-29T21:01:22.261Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01693653"
    },
    {
      "nct_id": "NCT04404283",
      "title": "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab vedotin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 239,
      "start_date": "2020-08-20",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-09-29T21:01:22.261Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Bonita Springs, Florida + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Bonita Springs",
          "state": "Florida"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04404283"
    }
  ]
}